• Mar 14, 2025

3 Reasons MANH is Risky and 1 Stock to Buy Instead

Manhattan Associates’s stock price has taken a beating over the past six months, shedding 39.3% of its value and falling to $164.02 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

  • Mar 14, 2025

Q4 Rundown: RTX (NYSE:RTX) Vs Other Defense Contractors Stocks

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how RTX (NYSE:RTX) and the rest of the defense contractors stocks fared in Q4.

  • Mar 14, 2025

3 Reasons to Sell PBI and 1 Stock to Buy Instead

While the broader market has struggled with the S&P 500 down 1.3% since September 2024, Pitney Bowes has surged ahead as its stock price has climbed by 39.6% to $9.27 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

  • Mar 14, 2025

3 Reasons IART is Risky and 1 Stock to Buy Instead

While the broader market has struggled with the S&P 500 down 1.3% since September 2024, Integra LifeSciences has surged ahead as its stock price has climbed by 31.6% to $22.79 per share. This performance may have investors wondering how to approach the situation.